Yesterday the
ACMD released a
report on the commissioning of substance misuse, and this sort of thing is
really the bread and butter of this blog, so I feel like I should overcome my
lethargy and comment on it. And it is
worth commenting on, because it makes some important points – but obviously I’m
going to challenge a few of its claims and assumptions, otherwise this would be
a pretty short and uninteresting post.
I’m going to do this in a format that’s pretty unusual for
this blog, which is to go through several of its conclusions and recommendations
in turn and assess them. This is partly
to be clear and systematic, and partly because I don’t have any other clever
ideas about how to tackle it.
First, then, it’s hard to argue with its statement that ‘reductions in local funding are the single
biggest threat to drug misuse treatment recovery outcomes being achieved in
local areas’. Fundamentally, we know
that the relationship with a client is crucial to good outcomes, and the less
money there is the more thinly spread staff time is and the less training
investment and time the staff will receive.
However, I’m less sold on the idea that the commissioning of treatment should be housed
within the NHS. There were good (pragmatic)
reasons why substance misuse treatment responsibilities ended up with local
authorities – not least because it was felt this agenda would get swallowed up
within the behemoth that is the NHS.
A lot of the document (particularly given that it starts
with a kind of history lesson on the funding of treatment since 1998) feels
like a lament for the
glory days of the NTA. Maybe this
isn’t fair, but I can certainly say that placing commissioning within the NHS would
not be anything like those days.
My experience of NHS commissioning is that – partly because
of the sheer scale of contracts – it’s not as detailed and hands-on as either
substance misuse work under the NTA or local authority commissioning more
generally. Let’s assume, for example,
that you were commissioning your local community health trust to deliver at
least the prescribing element of the treatment system. If you were sitting with the CCG, that would likely
(for ‘efficiency’) be embedded as just one element of a much bigger contract
covering all kinds of services – just have a look at the
website of Dorset HealthCare (DHC).
At one stage, as a commissioner, there were three levels of meetings at
which the Dorset prescribing would be considered: the overall CCG-DHC contract
review; a specific substance misuse CCG-DHC contract review sub-group so that
some people with direct knowledge of this service were in the room; and a
DAAT-DHC meeting where we actually discussed activity and performance. I wouldn’t want to go back to that, but I can
see how it would be justified on paper as managing the contract more ‘efficiently’.
And the idea that the budget wouldn’t get raided as much as
in local authorities is, to me, laughable.
NHS organisations, in my experience, find it much more difficult – quite
understandably, because of their size and the range of services they’re
providing – to give definite, accurate figures for staff time and costs of
specific elements of service (like substance misuse) than (small) dedicated
third sector agencies do. It requires inventing
quasi-market calculations like internal rents and charges. Sure, this is a consequence of the slightly
odd commissioning system – but that would make for an argument for getting rid
of the whole system, not simply shifting responsibility from one silo to
another.
Next, the report suggests clearer and more transparent financial reporting. And you can already predict my issue with
this: it’s really like looking inside the sausage factory. At a national level, aggregating figures, I
can believe this is helpful. I’d be much
more worried about doing this where comparisons are made at local authority
level, comparing one year with another. Huge
elements of local budgets – like res rehab, inpatient detox, drug costs,
dispensing fees – will not only vary significantly based on a few coincidences,
but bills can come at all sorts of times with all sorts of delays that skew the
figures from one year to the next. And would
it be timely? You often don’t get a bill
for the drugs you’ve prescribed for months, and then that bill might have to be
passed from the CCG or provider to the commissioner to pay, so the actual spend
on a crucial element of the budget would just be either forecasted or missed
off – particularly where prescribing arrangements have changed in a year (which
we’re told later in the document happens with worrying frequency). I worry that there’d be some kind of league
table of spend per head, which I just wouldn’t trust and could certainly be
manipulated.
However, other measures referred to sound sensible (and some
have already been mentioned in the Drug Strategy). It’s a good idea to try to assess what proportion
of the people with substance misuse issues living in an area have recently been
engaged in treatment – but then this is something that we already do, and have
done for years, based on information provided by PHE and before them the NTA.
The second conclusion of the report is very similar to the
first: ‘The quality and effectiveness of
drug misuse treatment is being compromised by under-resourcing’. Again, it’s all about the money. And again, I agree, but I don’t entirely sign
up to the recommendations. I’m not sure
how national bodies developing ‘clear standards’ would prevent a ‘drive to the
bottom’, unless there is actually more money in the system.
And I’m a bit uncomfortable with the phrasing in the report
that seems to suggest that everyone apart from nurses, doctors and
psychologists (and presumably psychiatrists?!) are ‘unqualified’. (Interesting also that social workers aren’t
name-checked.) They’re unregistered,
perhaps, but that’s quite a dichotomy to draw.
My view is very clear that there shouldn’t be this kind of dichotomy in
a treatment system, because (without sounding too trite) different people and professions
have different jobs and contributions to make.
Those registered staff should be focused on the functions that they are
uniquely well-placed to deliver.
But perhaps I’m being unfair. The report is saying that the Drug Strategy
Implementation Board should be defining what an appropriate balance of these (supposed)
two groups should be, and obviously I’d hope any final figure would be
reasonable and reflect this reality.
I’m still a little worried, though, that the implication is
that there aren’t enough registered professionals in the system at the moment,
and the proportion needs to be higher.
Whether we like it or not, raising the proportion of these professionals
will (in a world of even fixed, let alone reducing budgets) result in fewer
frontline staff. That is a trade-off
that commissioners and providers are having to deal with all the time in
service design.
The next conclusion is that there’s a disconnect between treatment services and wider health structures. I don’t know what I think about this. Personally, I’d be happy for treatment
commissioning to be part of the NHS, and there do need to be strong connections
with services. But the reference is made
to CCGs and STPs when plenty of crucial elements aren’t currently the responsibility
of CCGs – for example custody healthcare and mental health liaison and
diversion services sit with NHS England.
And that’s not to mention that better links with wider criminal justice services
like probation would be helpful.
Perhaps treatment commissioners aren’t managing it
currently, but given the wider needs of many service users, being commissioned
by the same organisation as social care, safeguarding, family services, sexual
health and housing shouldn’t be a bad thing.
Based on my experience, I’m pretty sure you’d find local authorities and
the LGA quickly complaining about the lack of connections with safeguarding and
family services if commissioning moved over to the NHS.
This isn’t to say that links to wider health services can’t
or shouldn’t be improved, but reading this does make me want to re-emphasise
the complexity of public services. Does the
recommendation really amount to anything more than the platitude that partnership
is good?
The fourth conclusion is that ‘frequent re-procurement of drug misuse treatment is costly, disruptive
and mitigates treatment recovery outcomes’.
I couldn’t agree more, and I’d point interested readers to my
long and hard-to-read commentary on exactly this from a few months ago.
But again I wonder how realistic and sensible the
recommendation is. It is suggested that commissioning
should be undertaken in cycles of 5 to 10 years. This would certainly remove some of the
churn, and it would basically mean there wasn’t commissioning. I think this is fine, and it certainly fits
with the direction of travel to accountable
care organisations, where the commissioners just hand responsibility over
to a single provider along with a budget for them to manage directly.
However, given the system at the moment, it would be an odd
thing to do. Imagine having written a 10
year contract in 2006. You’d have given
more money to the provider as budgets increased for a few years, and then in the
last four years or so you’d be reducing it by about 5% a year. There are reasons commissioners tend to go
for three year periods (as we’ve just done in Dorset), and it’s not just some
blind adherence to a (largely mythical) requirement of procurement regulations. The reality is that it’s risky to promise something
for a long period, and there’s something to be said – for both providers and
commissioners – in offering certainty and security for a relatively short
period, rather than guaranteed uncertainty for a longer period.
And actually, given that however you wrap it up the
impending budget challenges will mean significant service re-design if not now
then very soon, and possibly again in a few years, it’s not immediately obvious
that one long contract with a stable provider (or group of providers) is the
easiest or best way to do that. You
might find (perhaps based on that ‘balance’ of different types of staff) that
the organisation that’s best at providing a service in stable times of relative
plenty is not the same organisation you’d want at a time of tight budgets and
political upheaval. And perhaps there’s something
to be said for the idea that a new broom sweeps clean, when big changes are
required.
And that’s kind of what the document is getting at when it
warns that ‘a system that has been seen nationally and internationally as
highly successful is at risk of being undermined’. The new broom will be sweeping out a system
that’s good.
But to quote the irritating cliché, ‘we are where we are’. I sometimes wonder when I read commentaries
on commissioning whether people really understand that – particularly in
relation to substance misuse – this really isn’t about people maliciously or
naively reducing the budget. The overall
public health grant is being reduced, as is the broader grant to local
authorities, and there’s no indication that either will exist in a few years,
at which point local authorities will magically become ‘self sufficient’.
In reality, I’m not sure it would be responsible or sensible
to start a commissioning cycle in 2017 based on a ten year (or even five year)
period. The broader context is that
there is (a) ‘no money’ and (b) there are no reliable predictions on the wider
political or economic context.
To think about practical solutions, there is (as
I’ve written before) too much ‘churn’, and re-procuring services is often
hugely wasteful. But as well as
extending contract periods, there are other things that can be done to reduce
that churn, through having open, sensible processes, encouraging partnership
working, designing the procurement process to offer a range of opportunities,
and so on. In fact, all the bits of good
practice that commissioners have been being told and taught about for decades.
The final recommendation (and a bit of a tangent for this
blog post) is about research. The ACMD seems to be concerned that third
sector providers aren’t as well linked into structures for clinical research as
NHS providers. Research is a good thing,
and it’s probably just my sensitivity that makes this feel like another plea to
commission NHS providers or house commissioning within the NHS, but I do want
to offer an alternative perspective.
When we commissioned some research locally, it was actually
those NHS structures that meant the staff and service users within our NHS
provider found it far more difficult to engage in the process than those
involved with our third sector partners.
There were so many hoops to jump through for what was an innocuous piece
of research asking service users what they thought of services and how they
felt their recovery could be strengthened.
Perhaps what the ACMD mean is that the NHS is better at jumping
through those hoops. But it’s
interesting that it’s only at this point, in relation to research governance
within the NHS, that the ACMD chooses to make its recommendation on the basis
of the world as it is currently, rather than recommending a change to that
world, as it does with budget constraints and political and economic uncertainty.
Overall, there’s a lot of sense in this report, and it’s
hard to disagree with most of the conclusions, or indeed the principles behind
the recommendations, but fundamentally I’d suggest things are a lot more
complicated than they might seem. Of
course that’s partly my need to be contrarian and find something to disagree
with. (And citing ‘complexity’ is always
a good way to do that.) And it’s also
simply the inevitable result of writing a clear report with definite
conclusions. This is a policy report,
not a nuanced academic thesis about the challenges of commissioning drug
services in 2017.
But most of all, I think it just highlights that we need to
talk about commissioning, particularly of substance misuse treatment
services. If you caught me at another
moment, feeling less defensive, you’d hear me say our team should sit within
the CCG, so I certainly complain at this suggestion.
But as in my
presentation to New Directions this
year, I’d end by emphasising that the most important thing in commissioning or
providing a service is the people. Let’s
not get too hung up on structures, or where a desk sits. We can do most of this stuff from within local
authorities or the NHS, and there will be strengths and weaknesses either
way. More important is just to get on a
do good stuff on the ground, and try to ignore – or maybe even engage
constructively with – the inevitable ‘churn’ around you.
But if we do need to talk about commissioning, this report
certainly isn’t a bad place to start. I
just think as we conduct this conversation we need to be clear about how much
we’re focusing on pragmatism or principles, and, probably because of the job I
do, that seems to be where I depart from the ACMD approach.
Excellent thought provoking cogent and real world tested...as ever.
ReplyDeletePaul Hayes